Updated:
BioTime
BioTime is an asset manager with offices in Karlsruhe, Alameda, and Amsterdam. No investment details or principals are publicly disclosed.
BioTime
BioTime's founding year is not publicly documented. The firm lists offices in Karlsruhe, Germany, Alameda, California, and Amsterdam, Netherlands, but names no principals or investment team members on any accessible platform. Strategy and deployment data are absent from public sources. No known fund structures, stage preferences, or portfolio companies have been disclosed. The geographic footprint spans Western Europe and the U.S. West Coast, potentially indicating a transatlantic healthcare or life-sciences investment focus, but no deal evidence supports this. Scale and team size are unknown. No professionals count, AUM, or recent operational events have been reported. No philanthropic vehicles or adjacent structures have been identified. The firm's structural differentiator is its lack of public footprint — an opaque multi-city operation with no verifiable investment history. This may reflect an intentional low-profile posture or a newly established entity without public track record.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Karlsruhe
Corporate office
Karlsruhe, Germany
Additional offices
Alameda, United States · Amsterdam, Netherlands
Sector focus
Frequently asked questions
Who runs investment decisions at BioTime?
BioTime has not publicly named any investment decision-makers or team members. No leadership information is available from any source.
How does BioTime source proprietary deal flow?
There is no public information on BioTime's sourcing strategy. The firm does not disclose any deal origination methods or partnerships.
Is BioTime structured as a single family office or does it operate more like a venture firm?
BioTime's structure is unclear. It lists three global offices, which suggest an asset management operation, but no public filings or marketing materials clarify whether it is a family office, venture capital firm, or other entity.
Does BioTime participate in fund commitments or only direct deals?
No information is available about BioTime's investment approach—whether it makes fund commitments, direct investments, or uses other structures.
What investment stages does BioTime typically target?
BioTime has not disclosed any stage preference or investment focus. No known deals or portfolio companies are on record.
Which sectors does BioTime explicitly avoid?
BioTime has not publicly communicated any sector exclusions. Its focus is unknown.
Where does the underlying wealth come from?
The source of BioTime's capital is not publicly disclosed. No wealth origin information is available.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: